ROKIT Healthcare Signs $20.7M MOU with UAE Royal Investment Group

ROKIT Healthcare, a South Korean developer of AI-powered hyper-personalized organ regeneration platforms, has signed a strategic memorandum of understanding (MOU) with Master Investment Group (MIG), a UAE royal family-backed investment institution, for a direct equity investment of approximately $20.7 million USD (KRW 30 billion) and the establishment of a joint venture in the United Arab Emirates. The parties said MIG will provide the cash capital and ROKIT Healthcare will contribute its core AI organ regeneration platform technology as an in‑kind investment to the planned Middle East joint venture, tentatively named ROKIT MENA.

"Sheikh Abdullah's personal visit to Korea, even amid serious international tensions, is a testament to the overwhelming value of our AI regenerative medicine technology," said Yoo Seok-hwan, CEO of ROKIT Healthcare. "With this large-scale investment and JV establishment as a turning point, ROKIT Healthcare will leap forward as a game-changer leading the global AI organ regeneration field."

Context and deal details

The MOU follows a personal visit by H.H. Sheikh Abdullah bin Mohammed bin Sakr Al Qasimi, CEO of the Ras Al Khaimah (RAK) royal family and representative of MIG, who traveled to ROKIT Healthcare's headquarters in Seoul to review the company's AI-driven organ regeneration and anti-aging technology. The trip, which came amid heightened geopolitical tensions in the Middle East, was highlighted by both parties as an indication of strong commitment to the partnership.

MIG, described in the announcement as an anchor investor charged with attracting strategic industries and fostering infrastructure development, will commit roughly $20.7 million USD (KRW 30 billion) in capital to the JV. ROKIT Healthcare will transfer its AI organ regeneration platform technology to the joint venture as an in-kind contribution. The agreement anticipates the establishment of a local manufacturing facility in the UAE and the creation of AI-based regenerative medicine clinics and local commercial production capacity.

The announcement noted MIG's prior early-stage investments in global deep tech companies, including Nauticus Robotics, positioning the group as an investor with experience in scaling specialized technology businesses into new markets.

Outlook

ROKIT MENA is expected to use the UAE as a regional hub for commercial production and clinical deployment, with plans to expand a medical network into major Gulf Cooperation Council (GCC) countries, including Saudi Arabia, and onward into European markets. The company framed entry into the GCC — estimated in the release to encompass around 15 million potential patients — as completing a global direct-sales triangle spanning the United States, China, and the Middle East and Europe.

Both parties said they will finalize a detailed investment agreement in the near term and proceed with joint-venture establishment activities. The deal signals ROKIT Healthcare's bid to leverage Middle East capital and infrastructure to commercialize its AI-driven regenerative medicine technologies outside of Korea.

• Investor: Master Investment Group (MIG), UAE royal family-backed
• Target: ROKIT Healthcare (South Korea)
• Investment: ≈ $20.7M USD (KRW 30 billion)
• JV: Tentatively named ROKIT MENA
• Contributions: MIG – cash; ROKIT – AI organ regeneration platform (in‑kind)
• Planned footprint: UAE manufacturing, AI regenerative clinics, expansion to GCC and Europe